News
ATNM
7.83
-1.39%
-0.11
Analysts Offer Insights on Healthcare Companies: Altimmune (ALT), Kiora Pharmaceuticals (KPRX) and Actinium Pharmaceuticals (ATNM)
TipRanks · 21h ago
Actinium Pharmaceuticals Price Target Maintained With a $50.00/Share by HC Wainwright & Co.
Dow Jones · 2d ago
HC Wainwright & Co. Reiterates Buy on Actinium Pharma, Maintains $50 Price Target
Benzinga · 2d ago
Actinium Pharmaceuticals: A Strong Buy on Clinical Advancements and Strategic Positioning in the Radiopharmaceutical Sector
TipRanks · 2d ago
Weekly Report: what happened at ATNM last week (0318-0322)?
Weekly Report · 3d ago
Earnings week ahead: Walgreens Boots Alliance, Carnival, GameStop and more
Several key companies are set to release their earnings reports for the week of March 25 to 29. Walgreens Boots Alliance, Carnival, GameStop and more are among the companies scheduled to report next week. The week is shortened by a market holiday on Friday and will be shortened to one day.
Seeking Alpha · 4d ago
Analysts Offer Insights on Healthcare Companies: Precision BioSciences (DTIL) and Actinium Pharmaceuticals (ATNM)
TipRanks · 03/20 16:50
LIVE MARKETS-Big pharma's FOMO will lead to more radio M&A
Big pharma's FOMO will lead to more radio M&A, says Truist Securities. AstraZeneca's $2.4 billion deal to buy Fusion Pharmaceuticals is latest example of renaissance of radio-pharmaceutical drugs. Interest in the space has re-surged since 2011.
Reuters · 03/20 13:33
BUZZ-U.S. STOCKS ON THE MOVE-US energy sector, Avis, NuScale
The tech-laden Nasdaq dipped on Tuesday with chip stocks falling to more than two-week lows. The Dow Jones Industrial Average was up 0.67% as focus turned to the Federal Reserve's policy meeting. The top three S&P 500 percentage gainers were International Paper Co, up 10%.
Reuters · 03/19 17:48
Actinium Pharmaceuticals Is Maintained at Buy by Maxim Group
Dow Jones · 03/19 17:09
Actinium Pharmaceuticals Price Target Raised to $30.00/Share From $20.00 by Maxim Group
Dow Jones · 03/19 17:09
Maxim Group Maintains Buy on Actinium Pharma, Raises Price Target to $30
Benzinga · 03/19 16:59
Actinium Pharmaceuticals: A Strong Buy Amidst Industry Interest and Strategic Advancements
TipRanks · 03/19 16:45
Actinium spikes as H.C. Wainwright highlights buyout prospects after Fusion deal
Actinium spikes as H.C. Wainwright highlights buyout prospects after Fusion deal. Fusion Pharma (FUSN) agreed to be acquired by AstraZeneca in a $2.4B deal. Actinium Pharmaceuticals (ATNM) traded higher on Tuesday.
Seeking Alpha · 03/19 16:31
BUZZ-U.S. STOCKS ON THE MOVE-National Cinemedia, Crinetics Pharma, Nordstrom
The S&P 500 and the Nasdaq fell on Tuesday with most megacap and chip stocks weakening. The Dow Jones Industrial Average was up 0.56%. National Cinemedia, Crinetics Pharma, Nordstrom were up. The top three Nasdaq percentage gainers were International Paper, Boeing and Boeing.
Reuters · 03/19 16:05
Radiopharmaceutical Growth and M&A Potential: Actinium Pharmaceuticals Buy Rating Justified
TipRanks · 03/19 15:35
Actinium Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 03/19 15:29
Actinium Pharmaceuticals Price Target Maintained With a $50.00/Share by HC Wainwright & Co.
Dow Jones · 03/19 15:29
HC Wainwright & Co. Maintains Buy on Actinium Pharma, Maintains $50 Price Target
Benzinga · 03/19 15:19
AstraZeneca-Fusion deal reignites radiopharma space
AstraZeneca agreed to acquire its partner Fusion Pharma for $2.4B. The radiopharmaceuticals market is expected to reach more than $13B by 2032. The deal reignites interest in the radiopharma space. Other companies focused on the drug class also traded higher on the news.
Seeking Alpha · 03/19 12:19
More
Webull provides a variety of real-time ATNM stock news. You can receive the latest news about Actinium Pharmac through multiple platforms. This information may help you make smarter investment decisions.
About ATNM
Actinium Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing targeted radiotherapies to improve survival for people who have failed existing oncology therapies. The Company’s advanced pipeline candidates include Iomab-B (pre-BLA & MAA (EU)) and Actimab-A. Iomab-B is an induction and conditioning agent prior to bone marrow transplant. Actimab-A is a therapeutic agent, have demonstrated potential to extend survival outcomes for people with relapsed and refractory acute myeloid leukemia. The Company focuses on advance Iomab-B for other blood cancers and next generation conditioning candidate Iomab-ACT to improve cell and gene therapy outcomes. The Company holds patent applications including several patents related to the manufacture of the isotope Ac-225 in a cyclotron. Actinium-225 is a potent alpha-particle emitter that has high linear energy transfer capable of killing targeted cancer cells via double-strand breaks in DNA.